News

AZP-3601 Treatment Still Showing Positive Results in Phase 2 Trial

Daily treatment with AZP-3601, Amolyt Pharma’s investigational therapy for hypoparathyroidism, was well tolerated and allowed patients to discontinue standard supplement treatment, early data from a Phase 2a trial show. The treatment also rapidly normalized 24-hour urine calcium levels and improved bone health. The findings, from a first group of…

PTH Levels Help Predict Recovery 6 Months After Thyroid Surgery

Late recovery — longer than six months — from post-surgery hypoparathyroidism is not uncommon, and having levels of parathyroid hormone (PTH) within the normal range may indicate whether patients are more likely to recover, a study found. “PTH is a useful biomarker in predicting long-term recovery of parathyroid function,”…

Severe COVID-19 Suspected as Cause of Temporary Hypoparathyroidism

Severe COVID-19 could lead to the development of temporary hypoparathyroidism, a case report suggests. This report represents the third case of hypoparathyroidism secondary to severe COVID-19 infection noted in scientific literature. These rare instances, along with previous reports showing that the virus may worsen previously well-controlled hypoparathyroidism, highlight…

Child with Hypoparathyroidism Has Kidney, Parathyroid Transplant

The dual transplant of a kidney and a parathyroid gland was safe and effective at restoring parathyroid hormone (PTH) levels and turning back kidney disease, in an 11-year-old girl with congenital hypoparathyroidism and renal failure, a case study reports. “Simultaneous living donation and transplantation of a kidney and a…